Simple, secure, and scalable interpretation workflow
We are delighted to announce that we’ve expanded our QIAGEN® Clinical Insight™ (QCI™) solution to address the NGS interpretation and reporting needs of clinicians in oncology labs around the globe.
For germline cancers, we introduce the QCI Interpret for Hereditary Cancer solution, an evidence-based clinical decision support application. By evaluating genomic variants against a wealth of resources – including published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and clinical trials – this simple, secure, and scalable interpretation workflow provides a “one-stop shop” alternative to researching and scoring NGS variants from clinical workflows at countless sites and databases.
Increase your operational efficiency
We’ve also made the platform easy to personalize for your specific needs by providing the ability to build your own experience-based database with the variants you’ve assessed, which will increase the speed and accuracy of subsequent interpretations. We believe that QCI Interpret can increase your operational efficiency by reducing time, costs, and complexity to classify pathogenic variants, ultimately allowing you to focus your interpretation time on the high-risk variants that inform patient-specific medical management plans. The accuracy of risk assessment and resulting recommendations for screening enabled by QCI Interpret could mitigate cancer risk, either delaying its onset or detecting it at an earlier, more treatable stage.
Enabling the actual insights
The user-friendly interface was designed specifically for clinical lab teams, one of which is led by Dr. Madhuri Hegde, Professor of Human Genetics at the Emory University School of Medicine and Executive Director of the Emory Genetics Laboratory. “Clinical labs rolling out NGS-based tests are confronted with two key challenges: the complexity of turning molecular profiling information into precise medical recommendations, and the time and effort it takes to generate actionable reports,” Dr. Hegde commented. “QIAGEN Clinical Insight provides a rich and detailed, yet very clear and concise report that suggests management and treatment options based on the patient’s gene variations that profile their disease and outline causal links. It is this kind of interpretation that gives clinical value to the data, and what enables the actual insights into a patient’s specific disease and treatment options.”
For somatic cancer, we also announced updates to our Clinical Insight platform for somatic and inherited cancer testing, which launched in June 2015. The QCI enhancements include insights for diagnostic testing as well as monitoring and progression, support for copy number variations (CNVs) and fusion genes, and additional prognostics data from the literature. QCI now provides comprehensive cover of FDA- and EMA-approved drug labels, NCCN, ASCO and ESMO professional guidelines, and active genotype-related clinical trials to compliment literature reference and reported case databases.
The enhancements also add 32 hereditary cancer genes to QCI’s coverage, providing a more complete solution for laboratories to interpret and report on germline variants, including support for NGS comprehensive cancer panels testing for both somatic and inherited cancers. QCI now includes comprehensive curation of the hereditary cancer literature and curated clinical case counts for common heritable cancers including breast and ovarian cancer, Lynch syndrome, Peutz-Jegher syndrome, ataxia telangiectasia, neurofibromatosis, hereditary diffuse gastric cancer, familial prostate cancer, polyposis, and many more.
Read the press release
Learn more about QIAGEN Clinical Insight Interpret for Hereditary Cancer
Learn more about QIAGEN Clinical Insight Interpret for Somatic Cancer